Evidence map›Paper›PMID 40057668›Full record

ArticleCell biochemistry and biophysics2025

Micro-RNA-140-3p Acts as a Tumor Suppressor Gene in Acute Promyelocytic Leukemia by Targeting Hepatocyte Growth Factor.

RuiQi Lei, Xin Liu, YiTing Wu, JingYu Song, XiaoLi Lv, Jie Liu, Dan Guo, ShengJin Fan, HuiBo Li

Abstract read
PubMed Publisher
In one paragraph

Article in Cell biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

RuiQi LeiDivision of Hematology, Department of Medicine, The First Affiliated Hospital of Harbin Medical University, 23 Youzheng Street, Nan Gang District, Harbin, Heilongjiang Province, 150001, China.
Xin LiuDivision of Hematology, Department of Medicine, The First Affiliated Hospital of Harbin Medical University, 23 Youzheng Street, Nan Gang District, Harbin, Heilongjiang Province, 150001, China.
YiTing WuDivision of Hematology, Department of Medicine, The First Affiliated Hospital of Harbin Medical University, 23 Youzheng Street, Nan Gang District, Harbin, Heilongjiang Province, 150001, China.
JingYu SongDivision of Hematology, Department of Medicine, The First Affiliated Hospital of Harbin Medical University, 23 Youzheng Street, Nan Gang District, Harbin, Heilongjiang Province, 150001, China.
XiaoLi LvDivision of Hematology, Department of Medicine, The First Affiliated Hospital of Harbin Medical University, 23 Youzheng Street, Nan Gang District, Harbin, Heilongjiang Province, 150001, China.
Jie LiuDivision of Hematology, Department of Medicine, The First Affiliated Hospital of Harbin Medical University, 23 Youzheng Street, Nan Gang District, Harbin, Heilongjiang Province, 150001, China.
Dan GuoDivision of Hematology, Department of Medicine, The First Affiliated Hospital of Harbin Medical University, 23 Youzheng Street, Nan Gang District, Harbin, Heilongjiang Province, 150001, China.
ShengJin FanDivision of Hematology, Department of Medicine, The First Affiliated Hospital of Harbin Medical University, 23 Youzheng Street, Nan Gang District, Harbin, Heilongjiang Province, 150001, China. fansjhmu@163.com.
HuiBo LiDivision of Hematology, Department of Medicine, The First Affiliated Hospital of Harbin Medical University, 23 Youzheng Street, Nan Gang District, Harbin, Heilongjiang Province, 150001, China. lihuibo@hrbmu.edu.cn.

Funding

First Affiliated Hospital of Harbin Medical University 2021M02National Natural Science Foundation of China 81903966
6 · The paper itself

Abstract

MicroRNAs (miRNAs) are noncoding RNAs that regulate the expression of target genes after transcription, and play important roles in the differentiation of hematopoietic stem cells. Many miRNAs are related to the occurrence of acute promyelocytic leukemia (APL) and play roles in the treatment response. Recently, we demonstrated that several miRNAs are differentially expressed in patients with relapsed and newly diagnosed APL; for example, miR-140-3p is significantly downregulated in patients with relapsed APL. In this study, via a dual luciferase assay, we verified that one of the direct target genes of miR-140-3p is hepatocyte growth factor (HGF). After different lentiviruses were transfected into NB4 cells, and flow cytometry and proliferation assays confirmed that low expression of miR-140-3p inhibited the differentiation and apoptosis of NB4 cells and induced proliferation by promoting cell cycle progression. In summary, our findings suggest that hepatocyte growth factor is a target gene of miR-140-3p. Moreover, upregulation of miR-140-3p expression in APL cells inhibits cell proliferation, arrests cell cycle progression, and promotes apoptosis and cell differentiation. Monitoring the levels of miR-140-3p and HGF may predict the risk of disease recurrence, and interfering with the miR-140-3p / HGF pathway may have therapeutic potential for treating recurrent APL.

Indexed as

Genes, Tumor SuppressorHepatocyte Growth FactorLeukemia, Promyelocytic, AcuteMicroRNAsApoptosisCell DifferentiationCell Line, TumorCell ProliferationHumansHepatocyte Growth FactorHGF protein, humanMicroRNAsMirn140 microRNA, humanAcute promyelocytic leukemiaHGFMicroRNAsMiR-140-3pRecurrence

Identifiers

PMID40057668

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.